|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Capitalization1 |
94 860 | 132 331 | 131 461 | 181 878 | 210 243 | 206 072 | - | - |
Enterprise Value (EV)1 |
109 142 | 144 340 | 143 328 | 206 261 | 233 166 | 226 562 | 222 061 | 215 797 |
P/E ratio |
44,0x | 97,9x | 41,0x | 1 468x | 64,3x | 29,2x | 22,0x | 19,4x |
Yield |
3,74% | 2,78% | 2,80% | 2,44% | 2,14% | 2,28% | 2,36% | 2,45% |
Capitalization / Revenue |
4,29x | 5,43x | 4,94x | 4,86x | 4,74x | 4,49x | 4,07x | 3,80x |
EV / Revenue |
4,94x | 5,92x | 5,38x | 5,51x | 5,26x | 4,93x | 4,39x | 3,98x |
EV / EBITDA |
15,3x | 21,6x | 17,2x | 27,2x | 25,2x | 14,5x | 11,9x | 10,5x |
Enterprise Value (EV) / FCF |
69,3x | 72,5x | 37,3x | 42,3x | 26,7x | 28,7x | 20,5x | 17,2x |
FCF Yield |
1,44% | 1,38% | 2,68% | 2,36% | 3,74% | 3,49% | 4,87% | 5,82% |
Price to Book |
7,61x | 10,00x | 8,41x | 4,24x | 5,67x | 5,21x | 4,59x | 4,01x |
Nbr of stocks (in thousands) |
1 266 812 | 1 311 913 | 1 312 660 | 1 549 159 | 1 549 528 | 1 549 833 | - | - |
Reference price (USD) |
74,9 | 101 | 100 | 117 | 136 | 133 | 133 | 133 |
Announcement Date |
02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | 02/09/2023 | - | - | - |
1 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Net sales1 |
22 090 | 24 384 | 26 617 | 37 417 | 44 351 | 45 938 | 50 573 | 54 208 |
EBITDA1 |
7 140 | 6 686 | 8 311 | 7 586 | 9 237 | 15 661 | 18 692 | 20 532 |
Operating profit (EBIT)1 |
5 672 | 6 436 | 7 340 | 9 928 | 13 350 | 14 492 | 17 477 | 19 922 |
Operating Margin |
25,7% | 26,4% | 27,6% | 26,5% | 30,1% | 31,5% | 34,6% | 36,8% |
Pre-Tax Profit (EBT)1 |
1 993 | 1 548 | 3 916 | -265 | 2 501 | 9 090 | 12 626 | 14 902 |
Net income1 |
2 155 | 1 335 | 3 196 | 112 | 3 288 | 7 323 | 9 945 | 11 347 |
Net margin |
9,76% | 5,47% | 12,0% | 0,30% | 7,41% | 15,9% | 19,7% | 20,9% |
EPS2 |
1,70 | 1,03 | 2,44 | 0,08 | 2,11 | 4,55 | 6,05 | 6,84 |
Free Cash Flow1 |
1 575 | 1 990 | 3 838 | 4 872 | 8 717 | 7 899 | 10 825 | 12 552 |
FCF margin |
7,13% | 8,16% | 14,4% | 13,0% | 19,7% | 17,2% | 21,4% | 23,2% |
FCF Conversion |
22,1% | 29,8% | 46,2% | 64,2% | 94,4% | 50,4% | 57,9% | 61,1% |
Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,87 | 2,90 | 3,03 | 3,13 | 3,26 |
Announcement Date |
02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | 02/09/2023 | - | - | - |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
2023 Q3 |
2023 Q4 |
Net sales1 |
6 578 | 7 410 | 7 320 | 8 220 | 9 866 | 12 011 | 11 390 | 10 771 | 10 982 | 11 207 | 10 909 | 11 111 | 11 481 | 12 094 |
EBITDA |
1 972 | 2 284 | 2 692 | 1 880 | 1 114 | 1 900 | 2 187 | 1 896 | 2 579 | 2 574 | - | - | - | - |
Operating profit (EBIT)1 |
1 795 | 1 899 | 2 524 | 1 805 | 2 281 | 3 318 | 3 961 | 3 365 | 3 413 | 2 610 | 3 507 | 3 701 | 3 980 | 3 717 |
Operating Margin |
27,3% | 25,6% | 34,5% | 22,0% | 23,1% | 27,6% | 34,8% | 31,2% | 31,1% | 23,3% | 32,1% | 33,3% | 34,7% | 30,7% |
Pre-Tax Profit (EBT) |
853 | 1 167 | 1 608 | 764 | -2 001 | -636 | 553 | 247 | 922 | 778 | - | - | - | - |
Net income1 |
648 | 1 012 | 1 561 | 550 | -1 652 | -347 | 386 | 360 | 1 640 | 901 | 1 813 | 1 941 | 2 115 | 2 065 |
Net margin |
9,85% | 13,7% | 21,3% | 6,69% | -16,7% | -2,89% | 3,39% | 3,34% | 14,9% | 8,04% | 16,6% | 17,5% | 18,4% | 17,1% |
EPS2 |
0,49 | 0,78 | 1,19 | 0,42 | -1,10 | -0,22 | 0,25 | 0,23 | 1,05 | 0,58 | 1,16 | 1,24 | 1,36 | 1,32 |
Dividend per Share2 |
- | 1,90 | - | 0,90 | - | 1,97 | - | 0,93 | - | 1,97 | - | - | - | 2,95 |
Announcement Date |
11/05/2020 | 02/11/2021 | 04/30/2021 | 07/29/2021 | 11/12/2021 | 02/10/2022 | 04/29/2022 | 07/29/2022 | 11/10/2022 | 02/09/2023 | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Net Debt1 |
14 282 | 12 009 | 11 867 | 24 383 | 22 923 | 20 490 | 15 988 | 9 724 |
Net Cash position1 |
- | - | - | - | - | - | - | - |
Leverage (Debt / EBITDA) |
2,00x | 1,80x | 1,43x | 3,21x | 2,48x | 1,31x | 0,86x | 0,47x |
Free Cash Flow1 |
1 575 | 1 990 | 3 838 | 4 872 | 8 717 | 7 899 | 10 825 | 12 552 |
ROE (Net Profit / Equities) |
32,0% | 35,6% | 36,7% | 27,5% | 27,2% | 29,1% | 31,3% | 30,6% |
Shareholders' equity1 |
6 742 | 3 752 | 8 704 | 407 | 12 074 | 25 148 | 31 757 | 37 116 |
ROA (Net Profit / Asset) |
7,07% | 2,19% | 4,99% | 8,77% | 3,26% | 9,31% | 11,2% | 11,8% |
Assets1 |
30 480 | 61 015 | 64 053 | 1 277 | 100 924 | 78 657 | 89 158 | 95 964 |
Book Value Per Share2 |
9,84 | 10,1 | 11,9 | 27,7 | 23,9 | 25,5 | 29,0 | 33,1 |
Cash Flow per Share2 |
2,07 | 2,28 | 3,66 | 4,18 | 6,29 | 6,87 | 7,92 | 9,18 |
Capex1 |
1 043 | 979 | 961 | 1 091 | 1 091 | 1 685 | 1 903 | 2 028 |
Capex / Sales |
4,72% | 4,01% | 3,61% | 2,92% | 2,46% | 3,67% | 3,76% | 3,74% |
Announcement Date |
02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | 02/09/2023 | - | - | - |
1 USD in Million 2 USD |
|
| |
|
|
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval |
Capitalization (GBP) |
168 993 843 422 |
Capitalization (USD) |
206 072 461 402 |
Net sales (USD) |
44 351 000 000 |
Number of employees |
83 500 |
Sales / Employee (USD) |
531 150 |
Free-Float |
96,4% |
Free-Float capitalization (GBP) |
162 976 741 114 |
Free-Float capitalization (USD) |
198 735 158 113 |
Avg. Exchange 20 sessions (USD) |
15 455 285 480 |
Average Daily Capital Traded |
9,15% |
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|